Tempus has acquired the pharmacogenetics (PGx) assets of troubled OneOme, adding RightMed PGx capabilities and commercial partnerships to its diagnostics portfolio, GenomeWeb reported. Tempus said it could not elaborate on strategy but the deal brings OneOme’s lab approvals and health‑system relationships, supporting Tempus’ expansion in clinical genomics and PGx testing. Separately, Ovation.io and PrecisionLife announced a collaboration to analyze longitudinal multi‑omic data from 25,000 GLP‑1 users to build a mechanistic genotyping test predicting response and safety. The companies intend the test to inform payer coverage decisions and drug development. Together these moves illustrate rapid consolidation and productization in PGx and precision medicine: established testing platforms are being acquired and paired with large real‑world datasets to create coverage‑grade companion diagnostics for high‑impact therapeutic classes like GLP‑1s.